viewC4X Discovery Holdings PLC

C4X Discovery makes significant progress; hails start of Indivior trial, joins coronavirus initiative

“We remain committed to deliver and drive novel small molecule drugs against challenging targets towards clinical development," said CEO Clive Dix

C4X Discovery Holdings PLC -

C4X Discovery PLC (LON:C4XD) chief executive Clive Dix said he is “delighted” by the progress to date of the drug developer as he hailed the start of clinical trials of a treatment for opioid dependence.

It was one of a series of highlights included in the company’s latest business update from which investors also learned the group has begun a new partnership with the GEN-COVID Consortium in Italy.

The collaboration will deploy C4X’s Taxonomy3 platform technology to examine genetic data from coronavirus (COVID-19)  patients to identify genes specifically associated with severe types of the disease.

“The disease continues to spread throughout the world and a clear understanding of how it affects people differently remains elusive. We believe that genetics may play a role in explaining the differences in an individual's disease susceptibility, severity and prognosis,” CEO Dix said in a statement.

“This is a new area for C4XD and we are excited to be working on such an important project.”

Separately, Dix also said that a phase I, single ascending dose trial of the company’s Orexin-1 antagonist, C4X_3256, should be completed by the end of the year.

Meanwhile, its most advanced in-house programmes, NRF-2 and IL-17, “continue to move forward".

One of C4X’s lead NRF-2 molecules, C4X_6746, has shown significant efficacy in a pre-clinical model of inflammatory bowel disease (IBD), shareholders were told.

“This enables expansion of our commercial discussions beyond those partners already engaged in assessing the programme for pulmonary arterial hypertension and sickle cell disease,” Dix explained.

In a wide-ranging statement, C4X also said:

  • The lead optimisation stage has begun for its oral IL-17 inhibitor programme for the treatment of Psoriasis
  • Significant progress has been made on C4XD's early oral inhibitor programme for the treatment of IBD
  • And the LifeArc risk-share collaboration on an oral small molecule inhibitor programme for the treatment of haematological cancers and inflammatory disease continues to “progress well”

“We remain committed to deliver and drive novel small molecule drugs against challenging targets towards clinical development," Dix said concluded.

Quick facts: C4X Discovery Holdings PLC


Price: 32 GBX

Market Cap: £72.9 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...


C4X Discovery announce 'sizeable deal and one we're very proud of' with...

C4X Discovery's (LON:C4XD) Clive Dix talks Proactive London's Katie Pilbeam about their worldwide licensing deal with international drugs giant Sanofi worth up to €414mln. The group will receive €7mln upfront, plus €11mln in pre-clinical payments. The deal is for their oral IL-17A...

on 12/4/21

2 min read